Search This Blog

Wednesday, March 11, 2026

Foghorn $158.9M year-end cash, runway into 1H 2028, updates CBP, EP300 degrader oncology pipeline

 

Foghorn Therapeutics ends 2025 with $158.9M year-end cash and runway into 1H 2028, updates CBP and EP300 degrader oncology pipeline

  • Oncology pipeline update includes 2026 IND-enabling milestones for CBP and EP300 degrader programs.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)